ASX Linkedin Twitter               

 

Company News

13 February 2017 – Viralytics Receives $4.3 Million R&D Tax Incentive

23 November 2016 – Results of AGM Meeting

23 November 2016 – ASX Release – AGM Presentation

23 November 2016 – ASX Release – Chairman’s address to AGM

22 November 2016 – Viralytics Appoints Clinical Advisory Board

14 November 2016 – Promising Advanced Melanoma Results from KEYTRUDA Combination Trial announced at SITC

10 October 2016 – Viralytics presents at European Society Medical Oncology Congress

CAVATAK YERVOY Promising Results in Advanced Melanoma

Update on CAVATAK KEYTRUDA Combination trials

4 October 2016 – Viralytics presents at Oncolytic Virus Therapeutics Conference

25 August 2016 – Viralytics Annual Report and Full Year Financial Results

28 July 2016 – Viralytics MD Dr Malcolm McColl Interviewed on CommSec Executive Series

10 June 2016 – Edison Report – Three Cavatak/checkpoint combination trials

6 June 2016 – Further Positive Clinical Data Presented at ASCO

3 June 2016 – Viralytics MD Dr Malcolm McColl Interviewed on ABC TV The Business

19 April 2016 – Positive Clinical Data from CAVATAK and YERVOY Combination

19 April 2016 – CAVATAK Anti-Cancer Immune Activity in Tumour Micro-environment

19 April 2016 – Checkpoint Combination active in Preclinical Lung, Melanoma

18 April 2016 – Further CAVATAK™ Trial Data: Abstracts Released at AACR Meeting

17 March 2016 – Viralytics to present Clinical Data at AACR Annual Meeting

15 March 2016 – Positive CAVATAK Clinical Data Presented at 2016 EAU Congress

25 January 2016 – Viralytics Completes $4 Million Share Purchase Plan

14 December 2015 – Share Purchase Plan

14 December 2015 – Viralytics Completes $28 million Placement

9 December 2015  – Viralytics Receives $2.9 Million R&D Tax Incentive

18 November 2015  – Results of AGM Meeting

18 November 2015 – ASX Release – AGM Presentation

18 November 2015 – ASX Release – Chairman’s address to AGM

10 November 2015 – The Australian Clinical update boosts Viralytics

9 November 2015 – Positive CAVATAK Clinical Data Presented at 2015 SITC Annual Meeting

6 November 2015 – Viralytics and Merck Collaborate in Lung and Bladder Cancer

28 September 2015 – ASX Release – Viralytics presents data at European Cancer Congress

(Scientific Posters here)

28 September 2015 – ASX Release – VLA initiates Clinical Trial of CAVATAK and PD-1 Combination

26 August 2015 – Viralytics Annual Report and Full Year Financial Results

29 June 2015 – Viralytics MD Dr Malcolm McColl Interviewed on ABC TV The Business

17 June 2015 – Viralytics Presents CALM and STORM Clinical Trial Results at Oncolytic Virus Therapeutics Conference
(Scientific Posters here)

16 June 2015 – CAVATAK™ Presentations at Oncolytic Virus Therapeutics Conference Reinforce Potential in Bladder Cancer and Melanoma

9 June 2015 – Viralytics to Present Initial Positive Results of Clinical Trial of CAVATAK™ in Bladder Cancer at Oncolytic Virus Conference

2 June 2015 – Positive final results from CAVATAK Phase 2 Melanoma Trial

13 May 2015 – Viralytics to present final CALM Clinical Data at ASCO 2015

9 May 2015 – Good Weekend (The Age and The Sydney Morning Herald) Cold War Against Cancer

21 April 2015 – Viralytics Update on CALM and STORM Clinical Trials at American Association for Cancer Research Annual Meeting

18 Mar 2015 – Viralytics to present CAVATAK clinical data at AACR Annual Meeting

6 Mar 2015 – Bioshares: US Investors take note of Viralytics

27 Jan 2015 – Viralytics commences Clinical Trial of CAVATAK in Bladder Cancer

7 Jan 2015 – Sky Business News – Summer Money Interview with Dr Malcolm McColl
Courtesy of Sky News

19 Dec 2014 – Bioshares: Top Six Stock Picks – 2015

4 Dec 2014 – Commencement of Checkpoint Inhibitor Combination Trial

2 Dec 2014 – Viralytics receives $2.5 Million R&D Tax Incentive

28 Nov 2014  – Bioshares: “Viralytics – An Overlooked Investment Opportunity”

27 Nov 2014  – Results of AGM Meeting

27 Nov 2014  – Managing Director’s Address to AGM

27 Nov 2014  – Chairman’s Address to AGM

17 Nov 2014 – BBY: Initiation of Coverage

14 Nov 2014 – Viralytics Receives UK Approval to Commence Clinical Trial of CAVATAK in Bladder Cancer

7 Nov 2014 – Positive CAVATAKTM Combination Data Presented at 2014 Society for Immunotherapy of Cancer (SITC) Meeting
CAVATAK Immunotherapy Combination Poster

24 Oct 2014 – Bioshares: Viralytics and the Next Wave of Cancer Immunotherapies

21 Oct 2014 – Viralytics to present at Australian Microcap Investment Conference
Viralytics Investor Presentation

30 Sep 2014 – CAVATAKTM Immunotherapy Combination Demonstrates Superior Anti-cancer Activity
CAVATAK Immunotherapy Combination Poster

29 Sep 2014  – Dr Robert Andtbacka receives Best Poster in the Melanoma and other skin tumours category at the 39th European Society for Medical Oncology Congress.

ASX Release – Updated Positive Data from Phase 2 Trial of CAVATAK in Late-Stage Melanoma
Poster – CALM Study: Secondary Endpoints of a Phase II study of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, delivered intratumorally in patients with advanced malignant melanoma

17 Sep 2014 – Updated CAVATAK Results to be presented at ESMO 2014 Congress
CALM Study Abstract
CAVATAK and Checkpoint Inhibitors Abstract

8 Sep 2014 – Peter Turvey appointed to Viralytics Board

2 Sep 2014 – Channel 7 News Report “Brain Drain”
CAVATAKTM among several technologies featured – commencing at 2’35
Courtesy of Channel 7

27 Aug 2014 – Full Year Financial Results and Operational Highlights

23 July 2014 – Bioshares: 10th Bioshares Biotech Summit Investment Panel Report

17 Jul 2014 – Bell Potter Report: Melanoma therapy development gathering steam

4 Jul 2014 – OzEquities Report: Viralytics Overview and current Phase 2 Clinical Trial promising results

12 Jun 2014 – Channel 7 News Report: Cold Comfort
Courtesy of Channel 7

5 Jun 2014 – Edison Report: Keep CALM and carry on

3 Jun 2014 – Progress in CAVATAK Phase 2 Melanoma Trial

3 Jun 2014 – ASCO Poster: Progress in CAVATAK Phase 2 Melanoma Trial

2 Jun 2014 – NBN News Report: Common cold cancer treatment
Courtesy of NBN

15 May 2014 – CAVATAK Cancer Immunotherapy: Progress in Phase 2 Melanoma Trial

15 Apr 2014 – Edison Report: STORMing start to a transformational year ahead

14 Apr 2014 – CAVATAK activity in lung cancer presented at international oncolytic virus conference

14 Apr 2014 – Poster: CAVATAK activity in lung cancer

10 Apr 2014 – Audio of Dr Andtbacka AACR Conference Presentation on CAVATAK

8 Apr 2014 –AACR Slide Deck entitled CAVATAK™-mediated oncolytic immunotherapy in advanced melanoma patients

8 Apr 2014 – Positive Interim Phase 2 Trial Results for CAVATAK

2 Apr 2014 – Viralytics Corporate Video

25 March 2014 – ABC The Business Report: New Frontiers for Australia’s bio-tech industry (external link)

7 Mar 2014 – Bioshares Report: Viralytics Starts Phase I/II Storm Study With Intravenous Cavatak

6 Mar 2014 – General Meeting CEO Presentation

6 Mar 2014 – Viralytics commences STORM Phase 1/2 Clinical Trial

6 Mar 2014 – Anti-cancer activity of CAVATAK to be presented at prestigious US cancer conference

28 Feb 2014 – Viralytics’ $4.1m Entitlement Offer Closes Fully Subscribed

17 Feb 2014 – Shareholder Newsletter February 2014

31 Jan 2014 – Sky News Business Report: Transformational Capital Raising
Courtesy of Sky News

30 Jan 2014 – Viralytics $27 million transformational capital raising

8 Jan 2014 – Target enrolment achieved in CAVATAK™ USA Phase 2 melanoma trial

27 Nov 2013 – Leading US Oncologist joins Scientific Advisory Board

19 Nov 2013 – Results of AGM Meeting

19 Nov 2013 – Chairman Address to AGM

8 Nov 2013 – Investor & Shareholder Presentation

8 Nov 2013 – Further Strong Progress in CAVATAK phase 2 CALM trial

23 Oct 2013 – Viralytics receives $1.9 million in R&D Tax Incentives

18 Oct 2013 – Annual Report 2013

24 Sep 2013 – Edison Report: CAVATAK Phase II meets primary end point

18 Sep 2013 – Primary Endpoint Achieved in CAVATAK Phase II Melanoma Trial

11 Sep 2013 – MHRA Approval for UK Clinical Trial

28 Aug 2013 – Full Year Financial Results – Year Ending 30 June 2013

12 Aug 2013 – Edison Report: Cancer immunotherapy goes viral

7 Aug 2013 – Viralytics’ Patent Coverage Expanded

5 Aug 2013 – Viralytics trading on US OTCQX Marketplace

23 Jul 2013 – Investor and Shareholder Presentation

19 July 2013 – Poster: Interim CALM results

19 July 2013 – Strong interim results of CAVATAK in Phase 2 Trial

18 Jun 2013 – CAVATAK anticancer activity in bladder cancer model

18 Jun 2013 – Poster: CAVATAKTM synergy with standard therapies in bladder cancer

17 Jun 2013 – CAVATAK presentations at international OV conference

17 Jun 2013 – Poster: Investigation of CAVATAK and Chemotherapy on Lung Cancer

17 Jun 2013 – Poster: Combinatory effects of Docetaxel with CAVATAK

17 Jun 2013 – Poster: CAVATAK: Immune cell interactions and oncolytic activity in Leukemia

4 Jun 2013 – CAVATAK ASCO Poster & CALM Trial Recruitment Milestone Achieved

4 Jun 2013 – Poster: CAVATAK ASCO

16 May 2013 – Progress of CAVATAK Phase II study to be presented at ASCO

1 May 2013 – Shareholder Newsletter

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).